2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-185229
    CTR/AMYR agonist-1 3108097-26-0 98%
    CTR/AMYR agonist-1 is a CTR/AMYR agonist with EC50 values of 0.56-6.9 nM. CTR/AMYR agonist-1 can be used for the research of metabolic disease.
    CTR/AMYR agonist-1
  • HY-185234
    CTR/AMYR activator-1 3068779-36-9
    CTR/AMYR activator-1 (S configuration of compound 122) is a CTR/AMYR activator. CTR/AMYR activator-1 can be used in the research of bone diseases, metabolic diseases, cardiovascular diseases, and neurodegenerative diseases.
    CTR/AMYR activator-1
  • HY-185257
    Tryptamino-dUTP 1219930-95-6
    Tryptamino-dUTP is a nucleotide triphosphate analog modified at the 5-position (R) of uridine (dUTP).
    Tryptamino-dUTP
  • HY-185277
    6β-Hydroxy-7α-thiomethylspirolactone 42219-60-3
    6β-Hydroxy-7α-thiomethylspirolactone is a metabolite of Spironolactone (HY-B0561). 6β-Hydroxy-7α-thiomethylspirolactone can be used in studies of cirrhotic ascites.
    6β-Hydroxy-7α-thiomethylspirolactone
  • HY-186004
    G6PC modulator-1 237403-58-6
    G6PC modulator-1 is a G6PC modulator.
    G6PC modulator-1
  • HY-186043
    Menin-MLL-IN-35 2654080-48-3
    Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.
    Menin-MLL-IN-35
  • HY-186044
    Menin-MLL-IN-36 2654078-52-9
    Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.
    Menin-MLL-IN-36
  • HY-186081
    Ramiprilat acyl-β-D-glucuronide 1357570-22-9
    Ramiprilat acyl-β-D-glucuronide is an acyl glucuronide metabolite of Ramiprilat (HY-B0279). Ramiprilat acyl-β-D-glucuronide undergoes methylation on its glucuronic acid moiety during solid phase extraction with strong cation exchanger cartridges, forming a methylated derivative. Ramiprilat acyl-β-D-glucuronide undergoes in-source conversion to Ramiprilat in mass spectrometry, with conversion extent proportional to declustering potential voltage.
    Ramiprilat acyl-β-D-glucuronide
  • HY-186199
    α-Glucosidase-IN-117 2410538-77-9
    α-Glucosidase-IN-117 is a low-activity α-glucosidase (α-glucosidase) inhibitor belonging to the coumarin derivative class, with an inhibition rate of 19.51% at 100 μM. α-Glucosidase-IN-117 can be used in diabetes research.
    α-Glucosidase-IN-117
  • HY-19273A
    Rimeporide hydrochloride 187870-95-7 98%
    Rimeporide hydrochloride (EMD-87580 hydrochloride) is a potent and selective inhibitor of the Na+/H+ exchanger (NHE-1).
    Rimeporide hydrochloride
  • HY-19401A
    L-796568 free base 211031-01-5 98%
    L-796568 free base is a β(3)-adrenergic receptor agonist. L-796568 free base can be used for the research of obesity.
    L-796568 free base
  • HY-19436S
    Solabegron-d8 1250988-09-0 98%
    Solabegron-d8 (GW 427353-d8) is deuterium labeled Solabegron. Solabegron (GW 427353) is a selective β3-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 nM. Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome.
    Solabegron-d8
  • HY-19522R
    Seladelpar (Standard) 851528-79-5 98%
    Seladelpar (Standard) is the analytical standard of Seladelpar. This product is intended for research and analytical applications. Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis.
    Seladelpar (Standard)
  • HY-19542A
    N-Hexanoyl-L-erythro-sphingosine 189894-78-8 98%
    N-Hexanoyl-L-erythro-sphingosine (L-Ceramide-C6) is an ester product.
    N-Hexanoyl-L-erythro-sphingosine
  • HY-19657R
    Oxypurinol (Standard) 2465-59-0 98%
    Oxypurinol (Standard) is the analytical standard of Oxypurinol. This product is intended for research and analytical applications. Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout.
    Oxypurinol (Standard)
  • HY-19904A
    (+/-)-Adomeglivant 872260-47-4 98%
    (+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials.
    (+/-)-Adomeglivant
  • HY-19904B
    (+)-Adomeglivant 872260-19-0 98%
    (+)-Adomeglivant ((+)-LY2409021) is a potent and selective glycogenotropin receptor antagonist with glucose-lowering activity. (+)-Adomeglivant reduces fasting blood glucose levels in both healthy subjects and patients with type 2 diabetes. The use of (+)-Adomeglivant can help investigate the mechanisms of hyperglycemia in type 2 diabetes. The antagonistic effect of (+)-Adomeglivant makes it challenging to assess the metabolic consequences of postprandial hyperglycemia.
    (+)-Adomeglivant
  • HY-19904R
    Adomeglivant (Standard) 1488363-78-5 98%
    Adomeglivant (Standard) is the analytical standard of Adomeglivant. This product is intended for research and analytical applications. Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.
    Adomeglivant (Standard)
  • HY-19942A
    TD-5471 hydrochloride 530084-35-6 98%
    TD-5471 hydrochloride is a potent and selective full agonist of the human β2-adrenoceptor.
    TD-5471 hydrochloride
  • HY-19960R
    BCTC (Standard) 393514-24-4 98%
    BCTC (Standard) is the analytical standard of BCTC. This product is intended for research and analytical applications. BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
    BCTC (Standard)
Cat. No. Product Name / Synonyms Application Reactivity